Abbott Laboratories (ABT) Competitors

Abbott Laboratories (NYSE:ABT) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Does the media refer more to ABT or DXCM?

In the previous week, Abbott Laboratories had 96 more articles in the media than DexCom. MarketBeat recorded 113 mentions for Abbott Laboratories and 17 mentions for DexCom. DexCom's average media sentiment score of 1.36 beat Abbott Laboratories' score of 0.73 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	52 Very Positive mention(s)	13 Positive mention(s)	23 Neutral mention(s)	12 Negative mention(s)	3 Very Negative mention(s)	Positive
DexCom	12 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer ABT or DXCM?

Abbott Laboratories presently has a consensus target price of $144.47, suggesting a potential upside of 16.69%. DexCom has a consensus target price of $99.60, suggesting a potential upside of 18.73%. Given DexCom's stronger consensus rating and higher probable upside, analysts clearly believe DexCom is more favorable than Abbott Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.82
DexCom	0 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.91

Is ABT or DXCM more profitable?

Abbott Laboratories has a net margin of 32.43% compared to DexCom's net margin of 12.90%. DexCom's return on equity of 30.05% beat Abbott Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	32.43%	18.83%	10.88%
DexCom	12.90%	30.05%	10.00%

Which has more risk & volatility, ABT or DXCM?

Abbott Laboratories has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Do insiders & institutionals believe in ABT or DXCM?

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Which has better earnings & valuation, ABT or DXCM?

Abbott Laboratories has higher revenue and earnings than DexCom. Abbott Laboratories is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$41.95B	5.13	$13.40B	$7.71	16.06
DexCom	$4.03B	8.16	$576.20M	$1.34	62.60

Summary

DexCom beats Abbott Laboratories on 9 of the 16 factors compared between the two stocks.